Kangstem Biotech Co. Ltd (217730) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Kangstem Biotech Co. Ltd stock KRW 1,164, price KRW 1,712, that is 32.0% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Kangstem Biotech Co. Ltd
217730 · KQExpensive (fair value 32% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range 1,096 KRW – 4,615 KRW · fair‑value band 872.64 KRW – 1,454 KRW · the 1,712 KRW price screens above the 1,164 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Kangstem Biotech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases.
Show moreShow less
The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease.
It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration.
In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services.
Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
Stock analysis
Kangstem Biotech Co. Ltd (217730) currently trades at 1,712 KRW, while our estimate is 1,164 KRW, 32% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 872.64 KRW (bear) to 1,454 KRW (bull), the price of 1,712 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Kangstem Biotech Co. Ltd reported revenue of 3.6B KRW in FY2025 versus 12.4B KRW in FY2021, a compound −26.7%/yr. Reported net income was −10.5B KRW in FY2025.
Key figures
Market cap 160B KRW (≈ $120M) Micro · P/S ratio 57.8 · EPS (TTM) −123.04 KRW · Return on equity −47.9% · Return on assets (EBIT) −23.9% (5-year average) · Operating margin −944% · Revenue (TTM) 3.0B KRW · Revenue growth (YoY) −37.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).
What moves the price
The share trades about 63% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −32%, 217730 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Kangstem Biotech Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- PEG screener for stocks with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 217730 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 217730 |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs 217730 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 217730 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 217730 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 217730 |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs 217730 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 217730 |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs 217730 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 217730 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Kangstem Biotech Co. Ltd (217730) overvalued or undervalued?
What is the fair value of 217730?
What is the quality score of 217730?
What is the price target for Kangstem Biotech Co. Ltd (217730)?
What is the Kangstem Biotech Co. Ltd stock forecast for 2026?
What is the revenue of Kangstem Biotech Co. Ltd (217730)?
What is the intrinsic value of Kangstem Biotech Co. Ltd (217730)?
Is Kangstem Biotech Co. Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 217730?
How much is Kangstem Biotech Co. Ltd worth?
What do the bullish and bearish scenarios say about 217730?
How solid is the balance sheet of Kangstem Biotech Co. Ltd (217730)?
How far is 217730 from its 52-week high?
Which stocks are comparable to Kangstem Biotech Co. Ltd?
Is Kangstem Biotech Co. Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Kangstem Biotech Co. Ltd (217730)?
What should I pay attention to with Kangstem Biotech Co. Ltd right now?
Key figures of Kangstem Biotech Co. Ltd
How large is the market capitalisation of Kangstem Biotech Co. Ltd (217730)?
What is the P/S ratio of Kangstem Biotech Co. Ltd (217730)?
What are the earnings per share of Kangstem Biotech Co. Ltd (217730)?
What is the return on equity of Kangstem Biotech Co. Ltd (217730)?
What is the EBIT return on assets of Kangstem Biotech Co. Ltd (217730)?
What is the operating margin of Kangstem Biotech Co. Ltd (217730)?
How fast is revenue growing at Kangstem Biotech Co. Ltd (217730)?
How much free cash flow does Kangstem Biotech Co. Ltd (217730) generate?
How much net debt does Kangstem Biotech Co. Ltd (217730) carry?
Watch Kangstem Biotech Co. Ltd in the live analysis
One click puts Kangstem Biotech Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.